ArticleNature chemical biology2022
Selective G protein signaling driven by substance P-neurokinin receptor dynamics.
Open access · greenAbstract read
In one paragraph
Article in Nature chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 90 citations in OpenAlex.
- Intracellular pocket and ICL2 motifs govern G-protein coupling bias in NKThe Journal of biological chemistry · 2026Article
- Next-generation chemogenetic inhibition using a brain-permeant non-prescription agent.Signal transduction and targeted therapy · 2026Article
- Broadening the View: Substance P and Its Metabolism in Pruritus-Related Diseases.The Journal of dermatology · 2026Review
- Structurally defining neurokinin selectivity to improve NK2R agonists.Nature structural & molecular biology · 2026Article
- Article
- Review
- Mast Cells and Substance P: Neuroinflammatory Loops at the Molecular and Translational Clinical Levels.Biomolecules · 2026Review
- Nanobodies unlock new mechanisms to target G protein-coupled receptors.Molecular pharmacology · 2026Review
- Brain peptides in Alzheimer's disease - pathophysiology and therapeutic advances.Cell and tissue research · 2026Review
- Perioperative substance P/NK1R pharmacology: from PONV control to a testable cancer neuro-immune hypothesis.Frontiers in immunology · 2026Review
- Human Substance P Interactions with G Protein-Coupled Receptor NK1R Observed by NMR in Solution.Journal of the American Chemical Society · 2025Article
- Insights into G-protein coupling preference from cryo-EM structures of GNature chemical biology · 2025Article
- Exploring neurokinin-1 receptor antagonism for depression with structurally differentiated inhibitors.Experimental & molecular medicine · 2025Article
- Molecular basis of ligand binding and receptor activation at the human ANature communications · 2025Article
- Pituitary adenylate cyclase-activating polypeptide mediates bacterial endotoxin-induced fever via an effect on cyclooxygenase-2 and inflammatory cytokines.Scientific reports · 2025Article
- Neurokinin 1 receptor inhibition alleviated mitochondrial dysfunctionActa pharmaceutica Sinica. B · 2025Article
- Structural insight into the self-activation and G-protein coupling of P2Y2 receptor.Cell discovery · 2025Article
- Exploring the constitutive activation mechanism of the class A orphan GPR20.Acta pharmacologica Sinica · 2025Article
- Endomorphin-2 (Endo2) and substance P (SubP) co-application attenuates SubP-induced excitation and alters frequency plasticity in neonatal rat in vitro preparations.Respiratory physiology & neurobiology · 2025Article
- Antibodies expand the scope of angiotensin receptor pharmacology.Nature chemical biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Julian A Harris *Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Bryan Faust *Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Arisbel B Gondin *Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.ORCID http://orcid.org/0000-0002-1751-4062
Marc André Dämgen *Department of Computer Science, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-8229-7906
Carl-Mikael SuomivuoriDepartment of Computer Science, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-2445-8791
Nicholas A VeldhuisDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Yifan ChengDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA, USA. Yifan.Cheng@ucsf.edu.ORCID http://orcid.org/0000-0001-9535-0369
Ron O DrorDepartment of Computer Science, Stanford University, Stanford, CA, USA. ron.dror@stanford.edu.ORCID http://orcid.org/0000-0002-6418-2793
David M ThalDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. david.thal@monash.edu.ORCID http://orcid.org/0000-0002-0325-2524
Aashish ManglikDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA. Aashish.Manglik@ucsf.edu.ORCID http://orcid.org/0000-0002-7173-3741
Stanford University · USUniversity of California, San Francisco · USAustralian Research Council · AUDiscovery Institute · USHoward Hughes Medical Institute · US
Funding
The Stanford-SLAC CryoEM Center supplementU24GM129541 · NIGMS · STANFORD UNIVERSITY · PI CHIU, WAH, HEDMAN, BRITT · 2018 to 2023
$54.8MSTRUCTURAL BIOLOGY TRAINING PROGRAMT32GM008284 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KORTEMME, TANJA · 1988 to 2022
$10.1MAdvancing cryo-EM technology to address difficult biological questionsR35GM140847 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Yifan Cheng · 2021 to 2026
$2.1MAcquisition of an electron microscope for high-resolution single particle cryo-EMS10OD021741 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHENG, YIFAN · 2016 to 2016
$2.0MMolecular Mechanisms of Iron HomeostasisDP5OD023048 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MANGLIK, AASHISH · 2016 to 2020
$2.0MDiscovering the mechanism of GPCR-mediated arrestin stimulation to enable effective drug therapiesR01GM127359 · NIGMS · STANFORD UNIVERSITY · PI DROR, RON · 2018 to 2022
$1.5MLinux cluster for near atomic resolution single particle cryo-EMS10OD020054 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHENG, YIFAN · 2015 to 2015
$456kGPU Computing Enabled Linux Computer ClusterS10RR026814 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHENG, YIFAN · 2010 to 2010
$228kHoward Hughes Medical InstituteNCRR NIH HHS S10 RR026814NIGMS NIH HHS R01 GM127359NIGMS NIH HHS R35 GM140847NIGMS NIH HHS T32 GM008284NIGMS NIH HHS U24 GM129541NIH HHS DP5 OD023048NIH HHS S10 OD020054NIH HHS S10 OD021741
Abstract
The neuropeptide substance P (SP) is important in pain and inflammation. SP activates the neurokinin-1 receptor (NK1R) to signal via G
Indexed as
Signal TransductionAnimalsGTP-Binding ProteinsInflammationReceptors, Neurokinin-1GTP-Binding ProteinsReceptors, Neurokinin-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.